These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 6591221)

  • 41. Comparison of haloperidol and reduced haloperidol plasma levels in four different ethnic populations.
    Jann MW; Chang WH; Lam YW; Hwu HG; Lin HN; Chen H; Chen TY; Lin SK; Chien CP; Davis CM
    Prog Neuropsychopharmacol Biol Psychiatry; 1992 Mar; 16(2):193-202. PubMed ID: 1579637
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Blood levels of haloperidol and thioridazine during maintenance neuroleptic treatment of schizophrenic outpatients.
    Shvartsburd A; Sajadi C; Morton V; Mirabi M; Gordon J; Smith RC
    J Clin Psychopharmacol; 1984 Aug; 4(4):194-8. PubMed ID: 6470190
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Determination of plasma haloperidol concentrations by radioreceptor assay in schizophrenia: clinical utility.
    Santos JL; Ramos JA; Prieto P; Almoguera I; Vazquez C; Rubio ME; Cabranes JA
    Prog Neuropsychopharmacol Biol Psychiatry; 1989; 13(6):917-25. PubMed ID: 2813809
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Blood levels of haloperidol and clinical outcome in schizophrenia.
    Doddi S; Rifkin A; Karajgi B; Cooper T; Borenstein M
    J Clin Psychopharmacol; 1994 Jun; 14(3):187-95. PubMed ID: 8027415
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An open trial of buspirone added to neuroleptics in schizophrenic patients.
    Goff DC; Midha KK; Brotman AW; McCormick S; Waites M; Amico ET
    J Clin Psychopharmacol; 1991 Jun; 11(3):193-7. PubMed ID: 2066458
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Haloperidol decanoate v. fluphenazine decanoate as maintenance therapy in chronic schizophrenic in-patients.
    McKane JP; Robinson AD; Wiles DH; McCreadie RG; Stirling GS
    Br J Psychiatry; 1987 Sep; 151():333-6. PubMed ID: 3322467
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lack of correlation between the steady-state plasma concentrations of aripiprazole and haloperidol in Japanese patients with schizophrenia.
    Nakamura A; Mihara K; Nemoto K; Nagai G; Kagawa S; Suzuki T; Kondo T
    Ther Drug Monit; 2014 Dec; 36(6):815-8. PubMed ID: 24739668
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lower plasma levels of haloperidol in smoking than in nonsmoking schizophrenic patients.
    Shimoda K; Someya T; Morita S; Hirokane G; Noguchi T; Yokono A; Shibasaki M; Takahashi S
    Ther Drug Monit; 1999 Jun; 21(3):293-6. PubMed ID: 10365639
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interconversions between haloperidol and reduced haloperidol in schizophrenic patients and guinea pigs: a steady-state study.
    Chang WH; Lin SK; Jann MW
    J Clin Psychopharmacol; 1991 Apr; 11(2):99-105. PubMed ID: 2056148
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Haloperidol plasma levels and clinical response: a therapeutic window relationship.
    Van Putten T; Marder SR; Mintz J; Poland RE
    Am J Psychiatry; 1992 Apr; 149(4):500-5. PubMed ID: 1554036
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of rifampin on the plasma concentration and the clinical effect of haloperidol concomitantly administered to schizophrenic patients.
    Kim YH; Cha IJ; Shim JC; Shin JG; Yoon YR; Kim YK; Kim JI; Park GH; Jang IJ; Woo JI; Shin SG
    J Clin Psychopharmacol; 1996 Jun; 16(3):247-52. PubMed ID: 8784658
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serum and CSF levels of haloperidol by radioimmunoassay and radioreceptor assay during high-dose therapy of resistant schizophrenic patients.
    Rimón R; Averbuch I; Rozick P; Fijman-Danilovich L; Kara T; Dasberg H; Ebstein RP; Belmaker RH
    Psychopharmacology (Berl); 1981; 73(2):197-9. PubMed ID: 6785816
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Total and free plasma neuroleptic levels in schizophrenic patients.
    Tang SW; Glaister J; Davidson L; Toth R; Jeffries JJ; Seeman P
    Psychiatry Res; 1984 Dec; 13(4):285-93. PubMed ID: 6596586
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Plasma haloperidol levels and therapeutic response in acute mania and schizophrenia.
    Balant-Gorgia AE; Eisele R; Balant L; Garrone G
    Eur Arch Psychiatry Neurol Sci; 1984; 234(1):1-4. PubMed ID: 6489392
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Radio receptor assay of serum neuroleptic levels in psychiatric patients.
    Krska J; Sampath G; Shah A; Soni SD
    Br J Psychiatry; 1986 Feb; 148():187-93. PubMed ID: 2870755
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Plasma haloperidol levels: clinical response and fancy mathematics.
    Van Putten T; Marder SR; Mintz J
    Arch Gen Psychiatry; 1985 Aug; 42(8):835-8. PubMed ID: 4015328
    [No Abstract]   [Full Text] [Related]  

  • 57. Simultaneous determination of plasma haloperidol and its metabolite reduced haloperidol by liquid chromatography with electrochemical detection. Plasma levels in schizophrenic patients treated with oral or intramuscular depot haloperidol.
    Aravagiri M; Marder SR; Van Putten T; Marshall BD
    J Chromatogr B Biomed Appl; 1994 Jun; 656(2):373-81. PubMed ID: 7987490
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Haloperidol and reduced haloperidol plasma levels in selected schizophrenic patients.
    Ereshefsky L; Davis CM; Harrington CA; Jann MW; Browning JL; Saklad SR; Burch NR
    J Clin Psychopharmacol; 1984 Jun; 4(3):138-42. PubMed ID: 6736273
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Reduced haloperidol/haloperidol ratios after oral haloperidol and decanoate administration in schizophrenics.
    Chang WH; Lin SK; Juang DJ; Chen LC; Yang CH; Hu WH; Chien CP; Lam YF; Jann MW
    Prog Neuropsychopharmacol Biol Psychiatry; 1993 Jan; 17(1):105-12. PubMed ID: 8416597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.